Preimplantation Genetic Testing Market - Global Size, Share, Trends, Growth and Forecast Year ( 2022 – 2032 )
Preimplantation Genetic Testing Market Dynamics
Preimplantation Genetic Testing Market by Technology (Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescent In-Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Single Nucleotide Polymorphism (SNP), Others) Product & Service (Reagents & Consumables, Instruments, Software & Services) Procedure Type (Preimplantation Genetic Screening , Preimplantation Genetic Diagnosis ) Application (Aneuploidy ,Structural Chromosomal Abnormalities ,Single Gene Disorders ,X-linked Disorders, HLA Typing, Others) End User (Maternity Centers & Fertility Clinics, Hospitals, Diagnostic Labs, and Service Providers, Research Laboratories & Academic Institutes)
Market Size and Overview:
The preimplantation genetic testing (PGT) market has witnessed significant growth, with a steady compound annual growth rate (CAGR) of 10.5% from 2023 to 2032, reaching a market value of $2.9 billion in 2032. This growth can be attributed to the increasing demand for advanced genetic testing technologies in assisted reproductive procedures. PGT enables the detection of genetic abnormalities in embryos before implantation, ensuring healthier pregnancies and reducing the risk of genetic disorders. As awareness about PGT benefits rises among couples with a history of genetic diseases, the demand for PGT services has surged. The market encompasses various PGT methods, including preimplantation genetic screening (PGS) and preimplantation genetic diagnosis (PGD), among others. Key players in the PGT market are continually investing in research and development to enhance the accuracy and efficiency of testing techniques, thereby fueling the market's growth.
Preimplantation Genetic Testing Market: Report Scope
Base Year Market Size
Forecast Year Market Size
- Next Generation Sequencing (NGS)
- Polymerase Chain Reaction (PCR)
- Fluorescent In-Situ Hybridization (FISH)
- Comparative Genomic Hybridization (CGH)
- Single Nucleotide Polymorphism (SNP)
Product & Service:
- Reagents & Consumables
- Software & Services
- Preimplantation Genetic Screening (PGS)
- Preimplantation Genetic Diagnosis (PGD)
- Structural Chromosomal Abnormalities
- Single Gene Disorders
- X-linked Disorders
- HLA Typing
- Maternity Centers & Fertility Clinics
- Hospitals, Diagnostic Labs, and Service Providers
- Research Laboratories & Academic Institutes
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
Next Generation Sequencing (NGS) stands out as the largest segment in the PGT market due to its advantages, including cost-effectiveness, improved ability to detect embryos with differing results (mosaicism), enhanced detection of structural abnormalities, and increased automation, leading to reduced human errors.
Among the end users, Maternity Centers & Fertility Clinics hold the largest market share, driven by the increasing number of fertility centers and high treatment success rates.
North America stands as the dominant and most mature market for preimplantation genetic testing (PGT), primarily driven by the United States. The region's leading position can be attributed to the increasing healthcare spending and a growing population seeking assisted reproductive technology (ART) solutions. The European Union (EU) region holds the second-largest market share for PGT, driven by lifestyle changes and high infertility rates, particularly in countries like the United Kingdom, Germany, and Spain. In the Asia Pacific (APAC) region, the preimplantation genetic testing market is expected to witness the fastest expansion throughout the projection period Latin America demonstrates steady growth, propelled by urban development, a rising middle class, and a growing demand for landscaping services. Key markets within the Latin American region include Brazil, Mexico, and Argentina. The Middle East and Africa region is also witnessing steady development in the PGT market, with a focus on urban development, tourism, and a growing emphasis on green spaces and landscaping in both commercial and residential sectors. Key contributors to the market's growth in this region include the United Arab Emirates, Saudi Arabia, and South Africa.
The preimplantation genetic testing (PGT) market experiences significant growth driven by various factors. One of the primary drivers is the pivotal role of PGT as a tool in IVF genetic testing. PGT enables the examination of embryos beyond their superficial appearance, substantially reducing the chances of conceiving unhealthy embryos. This aspect greatly contributes to the growth of the market, as it enhances the success rates of healthy pregnancies and instills confidence in prospective parents.
Furthermore, lifestyle and environmental factors have led to an increase in infertility cases globally. Factors such as the consumption of alcohol, drugs, smoking, poor diet, stress, exposure to environmental toxins, and hormonal health problems have contributed to rising infertility rates. As a result, the demand for in-vitro fertilization (IVF) procedures, where PGT plays a critical role in identifying genetic abnormalities in embryos, has witnessed a notable surge, positively impacting the preimplantation genetic testing market.
Moreover, the market benefits from the development of savior siblings and an increased adoption of assisted reproductive technology (ART) in developing countries. The option to create savior siblings through PGT, providing potential treatments for genetic conditions in existing siblings, has garnered attention and expanded growth opportunities for the PGT market.
Additionally, the growing risk of fatal genetic, hereditary, and chromosomal diseases, such as Duchenne muscular dystrophy, Down syndrome, cystic fibrosis, triploidy, and thalassemia, has motivated patients to opt for PGT. The ability of PGT to detect and prevent the transmission of such diseases to offspring encourages its utilization, further driving market growth.
The preimplantation genetic testing market faces challenges such as high procedural costs and unsupportive government regulations, which can hinder its growth. One of the primary challenges in the Preimplantation Genetic Testing market is the ethical and societal considerations surrounding genetic testing and selection of embryos.
The preimplantation genetic testing (PGT) market is characterized by the presence of prominent players, each contributing to the advancement of genetic testing technologies. Leading companies in the PGT market include Oxford Gene Technology, Thermo Fisher Scientific Inc., SciGene Corporation, Agilent Technologies Inc., PerkinElmer Inc., Coopersurgical Inc., Abbott Laboratories, Illumina Inc., Natera Inc., Yikon Genomics, Beijing Genomics Institute (BGI), Genea Limited, Rubicon Genomics, Inc., and Oxford Gene Technology among other players.
For instance, in April 2022, Illumina Inc. provided financial assistance to a preeminent German hospital with the aim of improving the rate of genetic disease diagnosis in seriously ill children. Such collaborations and initiatives reflect the dedication of these companies to enhance healthcare outcomes and contribute to the progress of genetic testing in the medical field.
Furthermore, companies like Natera Inc. have demonstrated their expertise in cell-free DNA testing, presenting groundbreaking outcomes of real-world research. Their RenasightTM test has exhibited a high yield rate for positive genetic findings in patients with chronic kidney disease (CKD), showcasing their commitment to revolutionizing disease diagnosis and patient care.